80711-56-4

Usage

Uses

Used in Neuroscience Research:
5-hydroxy-3,3-dimethyl-2,3-dihydro-1H-indol-2-one is used as a research compound for studying the role of serotonin in mood regulation, sleep, and appetite. Its involvement in the regulation of circadian rhythms and the sleep-wake cycle makes it a valuable tool for understanding the underlying mechanisms of these processes.
Used in Psychiatry:
In the field of psychiatry, 5-hydroxy-3,3-dimethyl-2,3-dihydro-1H-indol-2-one is used as a potential therapeutic agent for depression, anxiety, and other mood disorders. Its role as a serotonin precursor suggests that it may help alleviate symptoms associated with these conditions by modulating neurotransmitter levels.
Used in Psychopharmacology:
5-hydroxy-3,3-dimethyl-2,3-dihydro-1H-indol-2-one is used in psychopharmacology to investigate its potential as a therapeutic agent for mood disorders. Its role in the breakdown of psilocin, the active compound in hallucinogenic mushrooms, also makes it a compound of interest in understanding the psychedelic effects of these substances.
Used in Metabolism Studies:
In metabolism studies, 5-hydroxy-3,3-dimethyl-2,3-dihydro-1H-indol-2-one is used to explore its role in the breakdown of psilocin and its potential involvement in the psychedelic effects of hallucinogenic mushrooms. This research can provide insights into the metabolic pathways and mechanisms underlying the psychoactive properties of these substances.
Used in Drug Development:
5-hydroxy-3,3-dimethyl-2,3-dihydro-1H-indol-2-one is used in drug development as a potential lead compound for the creation of new therapeutic agents targeting mood regulation, sleep disorders, and appetite control. Its role as a serotonin precursor and its potential effects on circadian rhythms and the sleep-wake cycle make it a promising candidate for the development of novel treatments in these areas.

Upstream product

• 632324-67-5 tert-butyl 3,3-dimethyl-2-oxo-2,3-dihydroindole-1-carboxylate 
• 19155-24-9 3,3-dimethyloxindole 
• 136764-87-9 2-methyl-2-(2-nitro-phenyl)-propionic acid methyl ester 
• 87234-57-9 1,3-Dihydro-3,3-dimethyl-5-methoxy-2H-indol-2-one 
• 111118-65-1 1,3-dihydro-3,3-dimethyl-5-methoxy-1-benzyl-2H-indol-2-one 

Relevant academic research and scientific papers

Chemistry of Tertiary Carbon Center in the Formation of Congested C?O Ether Bonds

Nucleophilic substitutions, including SN1 and SN2, are classical and reliable reactions, but a serious drawback is their intolerance for both bulky nucleophiles and chiral tertiary alkyl electrophiles for the synthesis of a chiral quaternary carbon center. An SRN1 reaction via a radical species is another conventional method used to carry out substitution reactions of bulky nucleophiles and alkyl halides, but chiral tertiary alkyl electrophiles cannot be used. Therefore, a stereospecific nucleophilic substitution reaction using chiral tertiary alkyl electrophiles and bulky nucleophiles has not yet been well studied. In this paper, we describe the reaction of tertiary alkyl alcohols and non-chiral or chiral α-bromocarboxamides as a tertiary alkyl source for the formation of congested ether compounds possessing two different tertiary alkyl groups on the oxygen atom with stereoretention.

LACTAM COMPOUND AS FXR RECEPTOR AGONIST

Disclosed is a compound as shown in formula (I), an optical isomer thereof or a pharmaceutically acceptable salt thereof, and the present invention relates to the use of same in the preparation of a drug for treating FXR-related diseases.

Design, synthesis and biological evaluation of novel human monoamine oxidase B inhibitors based on a fragment in an X-ray crystal structure

Herein we report our efforts of developing reversible selective hMAO-B inhibitors based on isatin, a fragment in an X-ray crystal structure. Five different scaffolds were designed and many compounds were synthesized. Among them, compound A3 demonstrated very high potency and isoform selectivity against hMAO-B, 11 and 13 times more potent (IC50 = 3 nM) and 23.64 and 6.8 times more selective than the marked drugs, selegiline and safinamide. However, the endeavors to modify the polar 3-one group of isatin, that is in a hydrophobic environment in the binding site of hMAO-B, to small nonpolar hydrophobic groups did not bring about improved hMAO-B inhibitors, which may challenge our understanding of molecular interactions and molecular recognition in biological systems.

Phenylaminopropanol derivatives and methods of their use

The present invention is directed to phenylaminopropanol derivatives of formulae I, II, and III: [image] or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromyalgia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, schizophrenia, and combinations thereof.

Synthesis of 1,3-dihydro-3,3-dimethyl-2H-indol-2-one derivatives as possible nonsteroidal cardiotonics

New substituted 1,3-dihydro-3,3-dimethyl-2H-indol-2-one derivatives 19-29 and 34-43 were synthesized and examined for their inotropic activity in isolated dog ventricular tissues. Among them, compound 26 (2-(2,3-dimethoxybenzylamino)-N-(3,3,7-trimethyl-2-oxo-2,3-dihydro-1H-i ndol-5-yl)acetamide) showed very potent activity.

3,3-dialkyl-and 3,3-alkylene-indoline derivatives, processes for their production and pharmaceutical compositions comprising them

3,3-Dialkyl- or 3,3-alkylene-indolines which are unsubstituted at the 1- and 2-positions and which are substituted at the 4- or 6-position by an optionally etherified hydroxy group or substituted at the 5- or 7-position by an etherified hydroxy group, as well as their physiologically-hydrolyzable and -acceptable esters. The said indolines and esters as well as their pharmaceutically acceptable acid addition salts possess analgesic activity.